Back to Careers

CEO Dr. Hanadie Yousef represents Juvena on 2 panels at BIO 2025 in Boston to discuss how emerging therapeutic categories are reshaping dealmaking strategies and how the success of GLP-1/GIP therapies in promoting weight loss is driving a new era in chronic disease treatments

Back to Careers

Dr. Hanadie Yousef participates in the World Economic Forum’s Innovator Communities Meeting and Global Technology Retreat- and shares her expert insights on 2 panels: “Breaking Barriers: Funding Frontier Tech” and “Innovation to Impact: Commercialization Insights from the Field”

Back to Careers

Director of Translational Biology and Pharmacology, Priya Handa, PhD, and Senior Director of Discovery and Platform, Thach Mai, showcased our research at the 23rd Biopharma Drug Discovery Nexus Conference in San Francisco

Back to Careers

CEO Dr. Hanadie Yousef shares insights on a panel, “Entrepreneurial Excellence in BioPharma: Lessons from the Frontlines,” at SynBioBeta – The Global Synthetic Biology Conference in San Jose

Back to Careers

CEO Dr. Hanadie Yousef shares an Industry Update on JUV-161 and our plans to initiate Phase 1 studies this year at the 2025 International MDF Conference in  Indianapolis

Back to Careers

Our Senior Director of Discovery and Platform, Dr. Thach Mai, attended Google Cloud Next ‘25 to explore cutting-edge AI and cloud innovations transforming drug discovery and precision therapeutics

Back to Careers

Dr. Hanadie Yousef gave a talk on “Building a Pipeline with Purpose: Turning a Platform into Strategic Asset Value” as an invited speaker at Fierce Pharma Engage BD&L Summit in San Diego

Back to Careers

Juvena was honored to present at the IGF and Insulin System in Physiology and Disease Gordon Research Conference! Our CSO and Co-Founder, Jeremy O’Connell, had a great opportunity to present our JUV-161 program and engage in insightful discussions on the latest advancements in IGF biology

Back to Careers

Our SVP of Drug Development, Dr. Banmeet Anand, presented Juvena’s clinical stage metabolic program (JUV-161) that enhances muscle regeneration for the treatment of sarcopenia and myotonic dystrophy type 1 (DM1) at the International Conference of Frailty and Sarcopenia in Toulouse, France

Back to Careers

Our CSO and Co-founder, Jeremy O’Connell, presented Juvena’s metabolic program discoveries at the UCLA Symposium on Anti-Obesity Treatments.